Nausea and vomiting are distressing symptoms in advanced cancer patients. The causes of nausea and vomiting are multifactorial. Among the causes is opioid therapy, the mainstay of cancer pain management. When nausea or other opioid side effects occur, it may hamper pain management and undermine the quality of life of cancer patients. Risperidone exerts an antiemetic effect in animals, but there has been no clinical report on its antiemetic activity. We conducted a retrospective chart review to examine whether risperidone is useful for opioid-induced nausea and vomiting in advanced cancer patients (n=20). Risperidone was given as doses of 1mg once a day. Complete response was observed in 50% of patients (10/20) for nausea and 64% (7/11) for vomiting. Sedation (n=2) was documented as an adverse effect. This observation suggests that risperidone can be an effective antiemetic drug in the treatment of refractory opioid-induced nausea and vomiting in advanced cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2006.10.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the safety and efficacy of ciprofol monotherapy versus combined propofol for painless gastroscopy.
Pak J Pharm Sci
January 2025
Department of Anesthesiology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Jiangsu, China.
Traditional sedatives like Propofol can lead to adverse effects. This study compares the safety and efficacy of Ciprofol monotherapy versus combined Propofol for painless gastroscopy. Patients underwent painless gastroscopy at our hospital from January 2023 to December 2023 were studied.
View Article and Find Full Text PDFAtropine plus omeprazole for acute gastritis: Efficacy and safety analysis.
Pak J Pharm Sci
January 2025
Jian'ou Municipal Hospital, Nanping, Fujian, China.
This article primarily discusses the efficacy and safety of atropine (ATR) plus omeprazole (OME) for the treatment of acute gastritis (AG). From May 2022 to May 2024, 95 AG patients were selected, including 50 cases treated with ATR+OME (observation group) and 45 cases with anisodamine (ADM) plus OME (control group). Comparative analyses of the following dimensions were then carried out: Clinical efficacy, safety (xerostomia, palpitations and headaches), symptom remission time (stomach pain, abdominal distension and nausea and vomiting), serum inflammatory factors (tumor necrosis factor [TNF]-α, interleukin [IL]-6 and interferon [IFN]-β) and plasma gastrointestinal hormones (epidermal growth factor [EGF], gastrin [GAS] and somatostatin [SS]).
View Article and Find Full Text PDFEffect of non-pharmacological interventions on chemotherapy induced delayed nausea and vomiting for tumors: a systematic review and Bayesian network Meta-analysis.
Complement Ther Med
January 2025
School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. Electronic address:
Objective: To evaluate the efficacy of non-pharmacological interventions in improving chemotherapy induced delayed nausea and vomiting symptoms using a network meta-analysis.
Methods: Four Chinese databases (CNKI, Wanfang Data Knowledge Service Platform, VIP, Sinomed) and five English databases (PubMed, Cochrane Library, Embase, Web of Science, CINAHL) were searched from the establishment of the database to April 2024. A Bayesian network meta-analysis was performed on the response rate to the improvement of chemotherapy induced delayed nausea and vomiting, as well as improvement in KPS score, under different non-pharmacological interventions by using R 4.
DRopEridol for Abdominal pain in the emergency department for Morphine Equivalent Reduction. The DREAMER study.
Am J Emerg Med
January 2025
Pharmacy Department, Wesley Medical Center, 550 N Hillside St, Wichita, KS 67214, United States of America.
Introduction: Droperidol is a dopamine-2 receptor antagonist in the class of butyrophenone antipsychotics with antiemetic, sedative, analgesic, and anxiolytic properties. In the postoperative setting, droperidol provides an opioid sparing effect and decreases nausea/vomiting. Another butyrophenone antipsychotic, haloperidol, has been shown to reduce morphine milliequivalents (MME) administered when used for abdominal pain in the emergency department (ED).
View Article and Find Full Text PDFMitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults.
J Clin Med
December 2024
Department of Pharmacy, CHOC Children's Hospital, Orange, CA 92868, USA.
: Cannabinoid Hyperemesis Syndrome (CHS), associated with long-term cannabinoid use, has been increasingly observed in emergency room visits as more states in the U.S. have legislatively permitted medical and recreational marijuana use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!